SABRINA HELLBUSCH: Open Payments
NPI 1629577515 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,708 in 109 payments from 15 companies in 2025. Trend: 2023 $1,373 · 2024 $1,484 · 2025 $1,708
Food & beverage: $1,633Education: $76
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 26 | $353 |
| ABBVIE INC. | 30 | $346 |
| Otsuka America Pharmaceutical, Inc. | 13 | $238 |
| Teva Pharmaceuticals USA, Inc. | 12 | $210 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $139 |
| Axsome Therapeutics, Inc. | 4 | $87 |
| E.R. Squibb & Sons, L.L.C. | 3 | $53 |
| Biogen, Inc. | 2 | $52 |
| Janssen Pharmaceuticals, Inc | 1 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
Products named: REXULTI, VRAYLAR, CAPLYTA, AUSTEDO XR, UZEDY, COBENFY, ZURZUVAE, ABILIFY MAINTENA.
Industry payments across NE — which companies pay providers there.
